Events Details
Oculus Innovative Sciences announces New Dermatology Division, IntraDerm Pharmaceuticals
Wednesday, January 07, 2015
Oculus Innovative Sciences, Inc. a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the launch of a new division, IntraDerm™ Pharmaceuticals, which is intended to develop and commercialize advanced dermatological products for the professional dermatology markets in the United States and internationally. Headquartered in Petaluma, California, IntraDerm Pharmaceuticals is staffed with a seasoned management and sales team who are well versed in the dermatology prescription markets in both the United States and Europe.
"We're excited about going to market with both a road-tested management and sales team and an inaugural portfolio of dermatology products formulated from our proven Microcyn® Technology platform," said Bob Miller, Oculus CFO and COO. "Microcyn has proven itself successful in both clinical studies and in daily clinical use in the resolution of skin dermatoses, the management of scars, and perhaps most telling, the reduction of pain and itch, which is the most common complaint dermatologists hear from their patients."
IntraDerm's first U.S. products are: Alevicyn™ Antipruritic Gel, which is for use by healthcare professionals in the management of pain, burning and itching associated with various dermatoses, including atopic and radiation dermatitis; and Alevicyn™ Dermal Spray, which is intended to be used by health care professionals in the management via debridement of wounds such as stage I-IV pressure ulcers, partial- and full-thickness wounds, diabetic foot ulcers, post-surgical wounds, first- and second-degree burns, grafted and donor sites. The Alevicyn products were launched in late 2014. A second product offering, Celacyn™ Prescription Scar Management Gel, is being launched this month throughout the United States.
Miller continued: "Having previously partnered our dermatology products, we understand firsthand the enormous potential for Microcyn Technology in the dermatology space, both in the United States and internationally. In tandem with our U.S. efforts, our European team launched multiple new Microcyn-based dermatology products in the EU this past November. We believe that by bringing these products to market with our own sales force and team of distributors, rather than relying on the efforts of a partner, we will be better able to control our own destiny and provide strong, consistent sales growth in the lucrative and concentrated dermatology space."
The EU dermatology products, which recently secured CE Mark approvals, include a scar management gel, antiseptic solution, gel for management of mild-to-moderate acne and an atopic dermatitis hydrogel. These four products were commercialized this past November at the Medica Trade Fair in Germany.
Source : http://www.marketwatch.com/
